Lung Cancer Staging and Prognosis

Area of Science:

• Oncology
• Cancer Staging
• Molecular Diagnostics

Background:

• The International Association for the Staging of Lung Cancer (IASLC) developed the seventh edition TNM staging system for non-small cell lung cancer (NSCLC).
• TNM staging is a primary prognostic factor for NSCLC recurrence and survival, with 5-year survival rates varying significantly by stage.

Purpose of the Study:

• To present the data-derived TNM classifications for NSCLC from the IASLC Lung Cancer Staging Project.
• To highlight the prognostic significance of TNM stage and explore emerging molecular markers for improved outcome prediction.

Main Methods:

• Analysis of a large international dataset to develop TNM classifications.
• Review of current research on molecular markers, including immunohistochemistry, microarray, and mutation profiling.
• Evaluation of PD-L1 as a potential predictive and prognostic biomarker in NSCLC.

Main Results:

• TNM stage is the most critical prognostic factor in NSCLC, followed by histologic grade, sex, age, and performance status.
• Despite extensive research, few molecular prognostic markers have achieved clinical adoption.
• PD-L1 shows potential as a predictive marker for immunotherapy response but may indicate poorer overall survival.

Conclusions:

• The TNM staging system remains fundamental for NSCLC prognostication.
• Future NSCLC outcome prediction will likely combine TNM staging with molecular tumor profiling for more precise, individualized estimates.
• This integrated approach promises to refine treatment algorithms and improve patient outcomes.